Discovery of the salusin-β receptor as a target for angiogenesis-related diseases
Discovery of a previously unknown receptor using a new ligand-receptor analysis technique
A group of researchers from Kitasato University and USHIO's consolidated subsidiary Protosera used Protosera's patented new Membrane Protein Library (MPL) technology and clarified that the β-chain of ATP synthase is a receptor of salusin-β, which exerts many bioactive effects, including potent hypotensive, bradycardic, parasympathetic activation, pro-atherosclerotic, and antidiuretic hormone secretion stimulation.
Products containing an ATP synthase β-chain derivative or a substance specifically binding to the ATP synthase β-chain as an active ingredient are new development candidate drugs against angiogenesis based on the action mechanism on the receptor side rather than on the ligand side, which are expected to have effects for the treatment and prevention of diseases such as multiple types of cancer, myocardial infarction, chronic inflammation, retinal angiogenesis, diabetic retinopathy, and arteriosclerosis obliterans.
These research results were published in Scientific Reports on December 14, 2018 (Japan time).
「Identification of the salusin-β receptor using proteoliposomes embedded with endogenous membrane proteins」
https://www.nature.com/articles/s41598-018-35740-6
For further information, please contact:
Protosera Inc.
E-Mail: info@protosera.co.jp